BioMarin Pharmaceutical (BMRN) Price Target Raised to $112 at UBS
Tweet Send to a Friend
UBS maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $112.00 (from $87.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
